Drug developers rawn to orphan drugs market

Breakthrough therapies for rare diseases command premium pricing, particularly if no alternatives exist

31-Mar-2014 - The global orphan drugs market presents plenty of opportunities for new drug development – while there are only 172 approved orphan therapies, over 6,800 orphan diseases exist according to the United States National Institute of Health (NIH). Advancements in drug discovery capabilities coupled ...

Dako and Epitomics enter into strategic alliance on developing and launching IHC diagnostic monoclonal antibodies

23-Mar-2011 - Dako Denmark A/S and Epitomics, Inc. announced that they have entered into a collaboration which will allow the companies to unite competencies to provide the Anatomic Pathology market with state-of-the-art antibodies.Dako's expertise within the field of human cancer diagnostics, including ...

BioSystem Development and BAC BV collaborate to bring purification ligands to high throughput biotherapeutic process development

08-Nov-2010 - BioSystem Development and BAC BV announced a collaboration to bring state-of-the-art high affinity ligands to the AssayMAP high-throughput micro-chromatography platform. This collaboration marks an essential objective toward growing a family of high-throughput tools for micro-scale purification ...

Top Pharmaceutical and Biotech companies face slow down in sales growth over 2008–14

01-Mar-2010 - Top pharmaceutical and biotech companies face a major slow down in sales growth over 2008–14 according to a new report by independent business analyst Datamonitor. The report title “Pharmaceutical Company Outlook to 2014” considers the forecast performance of the world’s biggest pharmaceutical ...

NattoPharma acquires MGP Diagnostics and secures rights to important patent

16-Oct-2008 - NattoPharma ASA has acquired all shares of MGP Diagnostics AS, securing ownership of a granted patent that is the key to the development of a new diagnostic test concept. This concept may determine the need for the natural vitamin K2 product Mena Q7(TM), to which NattoPharma has exclusive ...

Use of Therapeutic Monoclonal Antibodies Increasing in Europe

17-Sep-2008 - Despite high therapy costs and drug format limitations, the popularity of monoclonal antibodies (mAbs) is on the rise. Physicians are increasingly adopting mAbs because of their superior side effect profile, and continued research is expected to yield more innovative products. New analysis from ...

Tecan and the Monash Antibody Technologies Facility unveil custom monoclonal antibody production facility

05-Sep-2008 - The new Monash Antibody Technologies Facility (MATF) was officially opened at a ceremony attended by a number of dignitaries from the Australian government, academia and the life science industry. The newly refurbished, two hundred square meter facility houses cutting-edge equipment and boasts ...

Monoclonal antibody sales to almost double in coming years

02-Sep-2008 - In 2007 total global monoclonal antibody (mAb) sales reached $26 billion and are forecast to almost double to $49 billion by 2013. While small molecule drug sales will continue to make up the majority of total market sales, the mAb market, with a compound annual growth rate (CAGR) of almost 11% ...

Global Protein Therapeutics Market Dominated by Monoclonal Antibodies

11-Apr-2008 - According to the market research report "Global Protein Therapeutics Market Analysis", the Protein Therapeutic Market was valued in excess of US$ 57 Billion in 2006 and according to projections, it would grow at a CAGR 12.83% till 2010 The market is presently dominated by Monoclonal Antibodies ...

SemBioSys Genetics and Syngenta Enter Into Agreement on Protein and Antibody Purification Technology

Deal between biotech companies will strengthen capabilities in biopharmaceuticals

25-Feb-2004 - Calgary. Syngenta and SemBioSys Genetics, Inc. have entered into an agreement giving Syngenta access to SemBioSys' proprietary oilbody based Stratosome(TM) Biologics and StratoCapture(TM) Purification Systems for the development of Syngenta's biologic products. These two technologies hold the ...